Following discussions with Health Canada, GSK has highlighted safety information from the SMART study
Roxane Laboratories is to discontinue the sale and distribution of 'Orlaam'
European Commission, EMEA and FDA agree to exchange information
News from the Swedish Medical Products Agency
A nationwide campaign addressing the appropriate use of HRT has been launched by the US FDA.
Improved PCI outcomes with clopidogrel not altered by statins
Olanzapine- and risperidone-associated weight gain is correlated with increased leptin levels,
Venlafaxine appears to be less tolerable and less 'safe' than sertraline, but similarly efficacious,
Switching from NNRTI-containing HAART regimens to 'Trizivir'* improves total cholesterol levels
Zolpidem safer than zopiclone or lormetazepam?
Ursodeoxycholic acid treatment may lead to weight gain
Thiazolidinediones: congestive heart failure and pulmonary oedema
NSAIDs inhibit MI prevention effects of aspirin
Low prevalence of psychiatric disorders with levetiracetam
Sirolimus appears to be associated with an increased incidence of surgical wound complications,
Adalimumab/infliximab
Ciprofloxacin
Botulinum toxin A
Cefepime
Cisplatin
Clopidogrel
Clozapine
Cyclophosphamide/fludarabine
Cyclosporin/mycophenolate mofetil/prednisolone
Cyclosporin/prednisone/sirolimus
Gefitinib
Cyclosporin/sirolimus/tacrolimus
Gabexate
Heparin
HAART
Gemcitabine
Infliximab
Irinotecan
Immunosuppressants
Lamotrigine interaction
Levofloxacin
Oxaliplatin
Local anaesthetics
Penicillamine
Phenelzine interaction and withdrawal
Sodium phosphate
Streptokinase
Sertraline
Sulphasalazine
Tacrolimus
Tacrolimus
Valsartan
Terbinafine
Vincristine
Warfarin interaction
Tamoxifen